Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gotta wait it out
Hopefully the FDA will give GLYC the the green light after reviewing phase 3 data in June
Picked up a few heavy racks of shares under 2.95 today.
$GLYC
GLYC: Hey!!!! WHAT???? (HA-HA!!)
$GLYC: The chart is screaming bullflag breakout on 100day chart
Now at 2.50
Perfect BULL FLAG.
NICE
GO $GLYC
$GLYC Crazy runner here..on watch to see if it continues as insider bought a ton of shares..
https://stocktwits.com/soll/message/497100283
https://stockcharts.com/c-sc/sc?s=GLYC&p=D&b=5&g=0&i=0&r=1668953354914
yup and congrats on your other runner.
wow, new highs hitting right now!
and back to 2 bucks. lets see what tomorrow brings.
boing, and back up she goes.
manipulation bringing it …
..
down but lets see what happens.
here we go, breaking 2 bucks big time now.
its time to break 2 bucks and really move like it did in the past.
WOW WOW WOW CHIEF MEDICAL OFFICIER BOUGHT 200,000 SHARES $$$
he went from 0 shares to 200000 in two days. 2- 100000 shares buys 2 days
now 4 employees have bought shares.
WOOOOOOOOOOOOOOOOOW 63000 SHARE BUY $$$$$$$$$$$$$$$$
employees are buying toooooooooo
3 HUGE INSIDE BUYS BY 3 PEOPLE. 19K, 20K AND 25K $$$$$$$$$$$$$$$$
1.06/1.29 UP UP AND AWAY
Agreed. Things looking up. Load up while no one else wants it. ;)
Now is but time. The gap has filled, weak hands are out, corporate path is correct.
Depends at what level - if back to 2s first it’s a big loss till then
The Investment Case For GlycoMimetics
https://seekingalpha.com/article/4389595-investment-case-for-glycomimetics
News; $GLYC GlycoMimetics Program Data to be Highlighted Via Three Oral Presentations and Two Posters at 62nd American Society of Hematology Annual Meeting and Exposition
Data highlight the importance of early intervention with E-selectin inhibitors to disrupt inflammatory mechanisms driving acute vaso-occlusive crisis (VOC) in sickle cell disease (SCD) Additional presentations highlight multiple E-selectin inhibition strategies and their pot...
In case you are interested GLYC - GlycoMimetics Program Data to be Highlighted Via Three Oral Presentations and Two Posters at 62nd American Society of Hematology Annual Meeting and Exposition
Great buy at this price. I own a ton of it.
News; $GLYC New Pediatric and Secondary Endpoint Data from Rivipansel Phase 3 RESET Trial Presented at The Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) Meeting
- Data highlight the importance of early intervention with fast-acting E-selectin inhibitors to disrupt the underlying inflammatory mechanisms driving acute vaso-occlusive crisis (VOC) - Abstracts for two of GlycoMimetics’ wholly-owned product candidates, rivipansel and...
In case you are interested GLYC - New Pediatric and Secondary Endpoint Data from Rivipansel Phase 3 RESET Trial Presented at The Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) Meeting
This looks good. Surely this'll bring a lot of growth
News: $GLYC GlycoMimetics to Present at the Piper Jaffrey 31st Annual Healthcare Conference 2019
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at the Piper Jaffrey 31 st Annual Healthcare Conference in New York, New York, which takes place on December 3, 2019. Ms. King’s presentation is scheduled for 1...
In case you are interested GLYC - GlycoMimetics to Present at the Piper Jaffrey 31st Annual Healthcare Conference 2019
LONG 2.88 YESTERDAY!!! BOOOOOOOOOOOMAGE
* * $GLYC Video Chart 08-05-2019 * *
Link to Video - click here to watch the technical chart video
I CAN GIVE A RATS ASS WHY THIS POFS DROPPED. THIS WILL FKN BOUNCE.
GMI-1070 (rivipansel) Phase 3 data due second half of 2019. Possibly July, or August.
Great interview with GLYC CEO: https://www.twst.com/interview/interview-with-the-co-founder-and-ceo-glycomimetics-inc
TWST: When you say rational design, what do you mean by that?
Mrs. King: As contrasted to screening approaches where some people select small molecules by screening millions of compounds against the target, in our case what we are doing instead is understanding the native interaction and how the normal biology works, and then creating a molecule that will interact with that particular target. We are rationally designing it.
ASCO first week of June, imo this may see $25+ in June.
Just saw the news! Nicely timed lol.
news $16+ , unlucky call there son! GLYC
Offering at 11.50. I'm gonna go ahead and short this back down to that point.
Thank you!
Followers
|
20
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
165
|
Created
|
06/17/14
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |